Literature DB >> 1686184

Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics.

S Kapur1, R Ganguli, R Ulrich, U Raghu.   

Abstract

Adherence to prescribed medications is believed to be a major problem in medicine. However, actual medication taking behaviour is rarely measured as no reliable objective measures of adherence are available. 50 mg of riboflavin administered at night could be reliably detected in urine, under UV light, for the next 18-24 h. The ability of 20 schizophrenic outpatients to adhere to a once-a-night dosage was studied by dispensing riboflavin or placebo in a random sequence and testing the urine for UV fluorescence the next day. The majority of patients (80%) had errors between 40-80% of the times tested. Only age and sex predicted the level of adherence. Clinicians were very poor predictors of the error rates in their patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686184     DOI: 10.1016/0920-9964(91)90020-r

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

Review 1.  Modeling and simulation of adherence: approaches and applications in therapeutics.

Authors:  Leslie A Kenna; Line Labbé; Jeffrey S Barrett; Marc Pfister
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

2.  Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia.

Authors:  E Diaz; H B Levine; M C Sullivan; M J Sernyak; K A Hawkins; J A Cramer; S W Woods
Journal:  J Psychiatry Neurosci       Date:  2001-09       Impact factor: 6.186

3.  Medication compliance among the seriously mentally ill in a public mental health system.

Authors:  C Nageotte; G Sullivan; N Duan; P L Camp
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1997-02       Impact factor: 4.328

Review 4.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

5.  Riboflavin as an independent and accurate biomarker for adherence in a randomized double-blind and placebo-controlled clinical trial.

Authors:  V-M S Ramanujam; Fatima Nayeem; Karl E Anderson; Yong-Fang Kuo; Nai-Wei Chen; Hyunsu Ju; Lee-Jane W Lu
Journal:  Biomarkers       Date:  2016-12-23       Impact factor: 2.658

6.  A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia.

Authors:  Tony P George; Jennifer C Vessicchio; Kristi A Sacco; Andrea H Weinberger; Melissa M Dudas; Taryn M Allen; Cerissa L Creeden; Marc N Potenza; Alan Feingold; Peter I Jatlow
Journal:  Biol Psychiatry       Date:  2007-12-21       Impact factor: 13.382

7.  A randomized factorial trial of disulfiram and contingency management to enhance cognitive behavioral therapy for cocaine dependence.

Authors:  Kathleen M Carroll; Charla Nich; Nancy M Petry; Dorothy A Eagan; Julia M Shi; Samuel A Ball
Journal:  Drug Alcohol Depend       Date:  2016-01-13       Impact factor: 4.492

8.  The Nigerian antihypertensive adherence trial: a community-based randomized trial.

Authors:  Adebowale Adeyemo; Bamidele O Tayo; Amy Luke; Olugbenga Ogedegbe; Ramon Durazo-Arvizu; Richard S Cooper
Journal:  J Hypertens       Date:  2013-01       Impact factor: 4.844

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.